Product Information
GLIPIZIDE-METFORMIN 5-500 MG is a generic product labeled by Chartwell RX LLC, priced at $0.2023 per EA under NDC 62135073360. Its NADAC has been published 147 times since Dec 13, 2023.
FDA first approved this application on Jun 23, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5; 500 mg/1; mg/1
Manufacturer
Chartwell RX LLCNDC
62135073360
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GLIPIZIDE; METFORMIN HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA078728FDA Approved
6/23/2010
TE Code
AB
On Market Since
6/29/2010
Pharmacological Classes
Price Statistics
The NADAC for GLIPIZIDE-METFORMIN 5-500 MG has been published 147 times since Dec 13, 2023, and over the history we have for it it has declined 29.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2023 per EA |
|---|---|
| All-time high | $0.2850 (Dec 13, 2023) |
| All-time low | $0.1910 (Jul 22, 2026) |
| 52-week high | $0.2224 |
| 52-week low | $0.1910 |
| Median price | $0.2188 |
| Average price | $0.2235 |
| Largest weekly change | -18.3% (Nov 20, 2024) |
| Weeks tracked | 147 |
| Tracking since | Dec 13, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Glipizide and metformin hcl market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chartwell RX LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Glipizide and metformin hcl market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Biguanide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GLIPIZIDE-METFORMIN 5-500 MG?
The current National Average Drug Acquisition Cost (NADAC) for GLIPIZIDE-METFORMIN 5-500 MG, manufactured by Chartwell RX LLC, is $0.2023 per EA (NDC 62135073360), effective Sep 30, 2026.
How has the price of GLIPIZIDE-METFORMIN 5-500 MG changed over time?
Over the history we have for it, the NADAC for GLIPIZIDE-METFORMIN 5-500 MG has declined 29.0%. It has been tracked across 147 weekly CMS publications since Dec 13, 2023.
What are the highest and lowest recorded NADAC prices for GLIPIZIDE-METFORMIN 5-500 MG?
Since Dec 13, 2023, the NADAC for GLIPIZIDE-METFORMIN 5-500 MG has ranged from a low of $0.1910 (Jul 22, 2026) to a high of $0.2850 (Dec 13, 2023), with a median of $0.2188 per EA.
Are there cheaper alternatives to GLIPIZIDE-METFORMIN 5-500 MG?
No other NADAC-published product currently shares the active ingredient and strength of GLIPIZIDE-METFORMIN 5-500 MG in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures GLIPIZIDE-METFORMIN 5-500 MG?
GLIPIZIDE-METFORMIN 5-500 MG (NDC 62135073360) is labeled by Chartwell RX LLC, and CMS classifies it as a generic product.